Skip to main content
AKTX
NASDAQ Life Sciences

Akari Therapeutics 公布 1730 万美元净亏损，研发重点转向 ADC 管道

feedReported by Wiseek News
Sentiment info
Negative
Importance info
8
Price
$0.121
Mkt Cap
$4.119M
52W Low
$0.12
52W High
$1.58
Market data snapshot near publication time

summarizeSummary

Akari Therapeutics 在其 10-K 提交中报告了 1730 万美元的重大净亏损，并伴随着研发费用减少 60%，而这是公司战略性地转变其管道的结果。该公司现在优先考虑其基于 PH1 的 ADC 计划，启动 GMP 生产，并瞄准 2027 年第一季度的 1 期试验，同时暂停传统的 nomacopan 计划。该财务更新是在公司最近进行 1 比 40 的反向股票拆分之后，这凸显了其具有挑战性的财务状况。相对于其微型市值的巨额净亏损，加上对其管道的完全重优先排序，代表了公司运营和财务前景的重大变化。投资者应该关注 ADC 计划的进展和提到的“短期融资安排”的细节，这可能涉及进一步的稀释。

在该公告发布时，AKTX的交易价格为$0.12，交易所为NASDAQ，所属行业为Life Sciences，市值约为$411.9万。 52周交易区间为$0.12至$1.58。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Wiseek News。

show_chartPrice Chart

Share this article

Copied!

feed AKTX - Latest Insights

AKTX
Apr 27, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
Akari Secures Australian Patent for Core ADC Payload, Bolstering Global IP
Sentiment: Positive
View Wiseek Article
AKTX
Apr 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
ASCO Accepts Akari's AKTX-101 ADC Abstract, Bolstering Potential for KRAS Mutant Tumors
Sentiment: Positive
View Wiseek Article
AKTX
Apr 20, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Akari's AKTX-101 Demonstrates Superior Preclinical Potency in Cancer, Eyes Phase 1 Study
Sentiment: Positive
View Wiseek Article
AKTX
Apr 06, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
Akari Therapeutics Partners with WuXi XDC, Accelerating Novel ADC Payload IND Filing to Late 2026
Sentiment: Positive
View Wiseek Article
AKTX
Mar 30, 2026, 5:45 PM EDT
Source: Wiseek News
Importance Score:
8
Akari Therapeutics Posts $17.3M Net Loss, Shifts R&D Focus to ADC Pipeline
Sentiment: Negative
View Wiseek Article
AKTX
Mar 17, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Akari Therapeutics Announces 1-for-40 Reverse ADS Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
AKTX
Mar 04, 2026, 4:52 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Key Insider Dr. Ray Prudo Invests $906K in Warrants, Increasing Stake to 8.9%
Sentiment: Positive
View Wiseek Article
AKTX
Mar 04, 2026, 4:44 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Major Insider Samir Patel Invests $688K in Akari Therapeutics Warrants, Boosting Stake to 10.4%
Sentiment: Positive
View Wiseek Article
AKTX
Mar 02, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
Shareholders Approve Warrants Enabling Nearly 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
AKTX
Feb 03, 2026, 11:15 AM EST
Filing Type: DEF 14A
Importance Score:
9
Akari Therapeutics Schedules Shareholder Vote on Warrants Enabling Significant Dilution and Capital Raise
Sentiment: Neutral
View Wiseek Article